Neurocrine’s Tardive Dyskinesia Opportunity Could Support a Multi-Year Growth Runway
Neurocrine’s estimated 800,000-person tardive dyskinesia population could support years of prescription growth, but execution remains key.
BioNTech and Bristol Myers Squibb Trial Data Put Oncology Pipelines in Focus
New lung cancer trial data from BioNTech and Bristol Myers Squibb shifts attention to pipeline quality, partnership economics and execution.
AbbVie’s Skyrizi Expansion Gives Investors a New Test of Immunology Growth
A new subcutaneous induction option could strengthen Skyrizi’s role in AbbVie’s post-Humira strategy, though its financial impact remains un…
Parabilis’ FDA Alignment Gives Its Desmoid Tumor Program a Clearer Road Map
Parabilis’ FDA-aligned dose strategy and placebo-controlled pivotal trial design may reduce uncertainty around its desmoid tumor program.
Compass Therapeutics’ Tovecimig Data Published in Journal of Clinical Oncology
Peer-reviewed publication of Compass Therapeutics’ Phase 2/3 tovecimig study may shape investor sentiment ahead of regulatory next steps.
Zymeworks’ ZW191 Posts Strong Response Rates in Platinum-Resistant Ovarian Cancer
ZW191 produced confirmed response rates of 64.5% and 55.3% in a difficult-to-treat ovarian cancer trial, sharpening focus on Zymeworks’ pipe…
Teva's FDA Approval Adds a Fresh Catalyst for Healthcare Investors
Teva drew attention after an FDA approval, but its quoted price later stood at $40.21, down 1.009%, highlighting a mixed signal.
Tango Therapeutics Slides 13% Despite 82% Pancreatic Cancer Response Rate
Tango Therapeutics fell 13% despite an 82% response rate, highlighting how traders discount small-sample pancreatic cancer data.
Elicio’s Pancreatic Cancer Trial Misses Endpoint Despite Positive Subgroup Signal
Elicio’s Phase 2 pancreatic cancer trial missed its primary endpoint, while a subgroup signal raises questions rather than resolving camupep…
IDEAYA’s IDE849 Data Put Dose, Safety and Pipeline Economics in Focus
IDE849’s Grade 3+ adverse-event rates rose from 5% to 22.2% across doses, sharpening questions about development strategy and IDYA’s pipelin…
Rapport Director Buys Nearly $1 Million as Analyst Raises Price Target to $82
Insider buying and a higher $82 price target put Rapport Therapeutics’ clinical pipeline under the microscope.
Biohaven Stock Jumps 25% After FDA Accepts Resubmitted Vyglxia Filing
BHVN jumped 25% after the FDA accepted Biohaven’s resubmitted Vyglxia filing, but acceptance is not final drug approval.











